Pluristem files orphan drug application to US FDA for preeclampsia - 0 views
-
Alex Parker on 24 Feb 14PBR Staff Writer Published 21 February 2014 Israel-based Pluristem Therapeutics has submitted its application to the US Food and Drug Administration seeking Orphan Drug Designation for its PLacental eXpanded (PLX-PAD) cells for the treatment of severe preeclampsia.